The ADH4 antibody targets alcohol dehydrogenase 4 (ADH4), a member of the alcohol dehydrogenase (ADH) enzyme family encoded by the ADH4 gene in humans. ADH4. also known as class II ADH, is primarily expressed in the liver and gastrointestinal tract. It plays a role in oxidizing various substrates, including ethanol, retinol, and lipid peroxidation products, contributing to alcohol metabolism, retinoid homeostasis, and oxidative stress responses. Unlike other ADH isoforms, ADH4 exhibits distinct substrate specificity and catalytic efficiency, particularly in metabolizing larger alcohols and aldehydes.
ADH4 antibodies are essential tools for studying the enzyme's expression, localization, and function in physiological and pathological contexts. Researchers use these antibodies in techniques like Western blotting, immunohistochemistry, and ELISA to investigate ADH4's role in diseases such as alcoholism, liver disorders, and certain cancers. For example, altered ADH4 expression has been linked to alcohol-related tissue damage and carcinogenesis, making it a biomarker candidate. Additionally, ADH4 polymorphisms are associated with genetic predispositions to alcohol dependence.
Commercial ADH4 antibodies are typically raised against specific epitopes of the human ADH4 protein, requiring validation for species reactivity and application compatibility. Their utility extends to both basic research and clinical studies, aiding in understanding metabolic pathways and disease mechanisms.